Outcomes and implications of British Columbia’s ‘drug decriminalization initiative’ for health-oriented drug policymaking
By lBenedikt Fischer, Didier Jutras-Aswad, Bernard Le Foll, Daniel T. Myra
Highlights
•
The province of British Columbia (Canada) temporarily implemented a decriminalization initiative for personal drug possession/use (2023–2024) in contexts of a toxic drug death crisis.
•
The decriminalization initiative was a priori promoted as a “tool to end the overdose crisis” and widely expected to reduce adverse health outcomes from toxic drug use.
•
Emerging evaluation data indicate that the drug decriminalization initiative was not associated with population-level changes in drug use-related mortality (e.g., overdose deaths) or morbidity (e.g., hospitalizations).
•
Drug use decriminalization remains an essential step to align prohibition-based drug policy frameworks with public health and human rights principles, but must be approached realistically and designed sensibly.
•
To tangibly address toxic drug use-related harms, expanded measures are required that are effectively capable of preventing and reducing PWUDs’ exposure to and use of toxic drugs
International Journal of Drug Policy
Volume 150, April 2026, 105181